Hematology

Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.

Oral azacitidine improved overall survival and relapse-free survival, while maintaining health-related quality of life in patients with acute myeloid leukemia.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

A recent study analyzed nurse and patient preference when it came to the administration of rituximab in patients with blood cancer.

Following the approvals of tisagenlecleucel (tisa-cel; Kymriah) and axicabtagene ciloleucel (axi-cel; Yescarta), several research efforts have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas, according to Olalekan O. Oluwole, MBBS, MD, who added that although this modality has moved the needle forward, this approach is not without toxicity.

A pharmacist provides an overview of new intravenous cancer therapies that were approved in 2020.

CAR T-cell therapy may change the treatment paradigm for relapsed/refractory myeloma.

The investigational wholly-owned allogeneic chimeric antigen receptor T-cell therapy CTX110 demonstrated dose-dependent efficacy and responses in patients with relapsed/refractory CD19-positive B-cell malignancies.

An expert discusses recent advancements in the mantle cell lymphoma space.

It is imperative that patients diagnosed with blood cancer undergo the proper molecular testing, one expert says.

The FDA approved venetoclax plus azacitadine, decitabine, or low-dose cytarabine for the treatment of patients with newly diagnosed acute myeloid leukemia.

Oncology nurses are key players in promoting health heart practices after a patient finishes cancer treatment.

The FDA approved pembrolizumab for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma.

While CAR T-cell therapy is causing landmark changes to difficult-to-treat blood cancer populations, most patients have experienced some adverse events in clinical trials.

Although many patients will eventually relapse, the first remission is the deepest, according to one expert.

Nurses need to know which patients are at risk and the tools to use to diagnose cardiac toxicities.

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA has granted a priority review to a supplemental new drug application (sNDA) for crizotinib (Xalkori) in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma (ALCL), according to an announcement from Pfizer, Inc.

Patients with mantle cell lymphoma (MCL) who have high-risk biology, including blastoid variant, a Ki-67 score of at least 30%, or high p53 expression, had a significantly shorter failure-free and overall survival (OS), according to results of a retrospective trial.

Nurses should discuss fertility preservation with all eligible patients and provide them with up-to-date information to make their decision.

It is crucial that oncology nurses monitor for cardiac complications in their patients with hematologic malignancies. And when one is discovered, they must act.

Blinatumomab (Blincyto) monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant (HSCT) resulted a significant improvement in event-free survival (EFS) and a lower risk of recurrence in children with high-risk B-cell precursor (BCP­)–acute lymphoblastic leukemia (ALL).

The orally available belumosudil continues be promising in patients with chronic graft-versus-host disease (cGVHD) who have received 2 or more prior lines of systemic therapy

The FDA has approved CC-486 for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy who are not able to complete intensive curative therapy.

To effectively tailor treatment for transplant-ineligible patients with multiple myeloma in the frontline setting, factors such as frailty status must be taken into consideration, according to Smith Giri, MD, MHS.

Investigational CAR T-cell therapy products have demonstrated unprecedented responses rates with seemingly durable remissions in patients with relapsed/refractory multiple myeloma, explained Luciano J. Costa, MD.

The Food and Drug Administration (FDA) provided an update on breast-implant associated side effects that have been reported to the agency, including breast implant-associated anaplastic large cell lymphoma (BI-ALCL) and symptoms that are commonly referred to by patients as breast implant illness (BII).

The FDA has approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received 1 or more prior lines of therapy.